GSK’S Andrew Witty: Addressing Neglected Tropical Diseases and global health ...Nejmeddine Jemaa
Every day, Non Governmental Organization NGOs is confronted with the lack of access to adequate or affordable medical tools in the field. They face two major challenges the high cost of existing medicines on the one hand, and the absence of appropriate or effective treatments for many of the diseases affecting our patients on the other, we are talking about Neglected Tropical Disease NTD in the Least developed Countries LDCs.
Andrew Witty, Chief Executive Officer of Glaxo Smith Klein (GSK) delivered a speech at the Harvard Business School in Boston on February 2009 entitled “Big pharma a catalyst for Change” focused on two issues: a) promoting innovation to prevent or treat NTDs in the world’s Least Developed Countries by creating a “pharmaceutical patent pool”; b) improving the access to medicine in the poorer countries by lowering the prices of GSK’s medicines.
In deed, we are assisting a radical change in pharma Business model, we are moving from conflict to collaboration through the Medicines Patent Pool in the hope that it speed up access to newer medicines, and boost initiatives that make use of alternative financing mechanisms in order to develop new, more appropriate treatments that respond to medical needs.
On the other hand the pricing strategy dilemma facing the generic manufacturers and the non inclusion of HIV which is a major neglected disease in LDCs in the patent pool may compromise the success of such business model.
In order to deal with that two issues, GSK should include HIV drugs in their patent pool as other manufacturers and NGO are doing, and concerning the pricing strategy they should emphasize on the high quality of the original drug mandatory to eradicate this NTDs and communicate more on the fact that GSK will invest 20% of these drugs profit to improve the infrastructure of these LDCs.
This is part of the MaRS BioEntrepreneurship series.
Speaker: Lynne Zydowsky, Ph.D., Managing Principal Zydowsky Consultants
* Explore the development of regulated drugs and devices
* Understand where and how value is generated in the pharmaceuticals industry
* Appreciate the interplay between science and business in a biotech company
To download a copy of the audio for this presentation, please go to:
http://www.marsdd.com/bioent/oct16
For the event blog and Q+A, please see:
http://blog.marsdd.com/2006/10/17/bringing-together-art-and-science/
GSK’S Andrew Witty: Addressing Neglected Tropical Diseases and global health ...Nejmeddine Jemaa
Every day, Non Governmental Organization NGOs is confronted with the lack of access to adequate or affordable medical tools in the field. They face two major challenges the high cost of existing medicines on the one hand, and the absence of appropriate or effective treatments for many of the diseases affecting our patients on the other, we are talking about Neglected Tropical Disease NTD in the Least developed Countries LDCs.
Andrew Witty, Chief Executive Officer of Glaxo Smith Klein (GSK) delivered a speech at the Harvard Business School in Boston on February 2009 entitled “Big pharma a catalyst for Change” focused on two issues: a) promoting innovation to prevent or treat NTDs in the world’s Least Developed Countries by creating a “pharmaceutical patent pool”; b) improving the access to medicine in the poorer countries by lowering the prices of GSK’s medicines.
In deed, we are assisting a radical change in pharma Business model, we are moving from conflict to collaboration through the Medicines Patent Pool in the hope that it speed up access to newer medicines, and boost initiatives that make use of alternative financing mechanisms in order to develop new, more appropriate treatments that respond to medical needs.
On the other hand the pricing strategy dilemma facing the generic manufacturers and the non inclusion of HIV which is a major neglected disease in LDCs in the patent pool may compromise the success of such business model.
In order to deal with that two issues, GSK should include HIV drugs in their patent pool as other manufacturers and NGO are doing, and concerning the pricing strategy they should emphasize on the high quality of the original drug mandatory to eradicate this NTDs and communicate more on the fact that GSK will invest 20% of these drugs profit to improve the infrastructure of these LDCs.
This is part of the MaRS BioEntrepreneurship series.
Speaker: Lynne Zydowsky, Ph.D., Managing Principal Zydowsky Consultants
* Explore the development of regulated drugs and devices
* Understand where and how value is generated in the pharmaceuticals industry
* Appreciate the interplay between science and business in a biotech company
To download a copy of the audio for this presentation, please go to:
http://www.marsdd.com/bioent/oct16
For the event blog and Q+A, please see:
http://blog.marsdd.com/2006/10/17/bringing-together-art-and-science/
Adrian Towse's slides from a session will exploring how the benefits of antibiotics can best be captured in HTA, and how we should pay for them when their value may depend on restricting their use.
Author(s) and affiliation(s): Adrian Towse, Office of Health Economics
Conference/meeting: Health Technology Assessment International (HTAi) 2018
Location: Vancouver, Canada
Date: 03/06/2018
Analysis of drivers that cause restricted access to funding for smaller biotech companies.
A detailed reviewed of the steps
venture capitalists and companies are
taking — models such as fail-fast R&D, asset-centric funding and more.
Proposal of a model that
could radically change R&D by taking a
much more holistic approach to drug
development, sharing information to
learn in real time across the cycle of care
and fundamentally changing how risk
and reward are allocated.
New Product Planning in the Pharmaceutical IndustryAnthony Russell
Lecture presented in the Competitive Intelligence and Pricing course as part of the University of Southern California Master of Science in Healthcare Decision Analysis program. Presented on June 14, 2020 at USC via Zoom. The lectures gives an overview of what new product planning is in the pharmaceutical industry, what tools are used during new product evaluations, and the key elements of a new product business case. The lecture includes a couple of case studies to be worked on by the class.
its not my personal work presentation but taken from lecture ppt from university of San Diego, california.
Its about the drug discovery process, its development and its commercialization.
The Future Landscape of Covid-19 Vaccine MarketMehdiMehdiyev4
We believe that assessing the potential market for COVID-
19 vaccines is necessary in terms of reevaluating the risk/reward ratio of certain vaccine developing companies.
In addition, an overly utopian outlook for a potential COVID-19 vaccine market may lead to
disappointment and negatively affect future vaccine developers. And this concerns us more.
HorseTech Conference Cheltenham 15/16 March 20223GDR
Speakers who will present on 15-16th March 2022 at the HorseTech Conference Cheltenham (and can be watched via the completely FREE livestream). For full details and to register:
https://horsetechconference.com/cheltenham/
DOCTORS AND SOCIAL MEDIA webinar (delivered by Liz Price, MDDUS senior risk a...3GDR
These slides were used for a MDDUS webinar that aimed to explore the legislative and regulatory risks involved in doctors personal and professional use of social media, and in relation to responding to and engaging with patients via this media.
The objectives were to raise awareness of the common medicolegal risks associated with doctors personal use of social media.
To raise awareness of the common medicolegal risks associated with doctors professional use of social media. To explore ways in which doctors can most appropriately respond to patient feedback and contacts via online platforms.
Participants are equipped to apply the knowledge gained in the webinar to risk assess and safely manage their online activities.
Provides guidance to enable improvement of personal practice in this area:
More Related Content
Similar to Structural market access challenges anti-infectives
Adrian Towse's slides from a session will exploring how the benefits of antibiotics can best be captured in HTA, and how we should pay for them when their value may depend on restricting their use.
Author(s) and affiliation(s): Adrian Towse, Office of Health Economics
Conference/meeting: Health Technology Assessment International (HTAi) 2018
Location: Vancouver, Canada
Date: 03/06/2018
Analysis of drivers that cause restricted access to funding for smaller biotech companies.
A detailed reviewed of the steps
venture capitalists and companies are
taking — models such as fail-fast R&D, asset-centric funding and more.
Proposal of a model that
could radically change R&D by taking a
much more holistic approach to drug
development, sharing information to
learn in real time across the cycle of care
and fundamentally changing how risk
and reward are allocated.
New Product Planning in the Pharmaceutical IndustryAnthony Russell
Lecture presented in the Competitive Intelligence and Pricing course as part of the University of Southern California Master of Science in Healthcare Decision Analysis program. Presented on June 14, 2020 at USC via Zoom. The lectures gives an overview of what new product planning is in the pharmaceutical industry, what tools are used during new product evaluations, and the key elements of a new product business case. The lecture includes a couple of case studies to be worked on by the class.
its not my personal work presentation but taken from lecture ppt from university of San Diego, california.
Its about the drug discovery process, its development and its commercialization.
The Future Landscape of Covid-19 Vaccine MarketMehdiMehdiyev4
We believe that assessing the potential market for COVID-
19 vaccines is necessary in terms of reevaluating the risk/reward ratio of certain vaccine developing companies.
In addition, an overly utopian outlook for a potential COVID-19 vaccine market may lead to
disappointment and negatively affect future vaccine developers. And this concerns us more.
HorseTech Conference Cheltenham 15/16 March 20223GDR
Speakers who will present on 15-16th March 2022 at the HorseTech Conference Cheltenham (and can be watched via the completely FREE livestream). For full details and to register:
https://horsetechconference.com/cheltenham/
DOCTORS AND SOCIAL MEDIA webinar (delivered by Liz Price, MDDUS senior risk a...3GDR
These slides were used for a MDDUS webinar that aimed to explore the legislative and regulatory risks involved in doctors personal and professional use of social media, and in relation to responding to and engaging with patients via this media.
The objectives were to raise awareness of the common medicolegal risks associated with doctors personal use of social media.
To raise awareness of the common medicolegal risks associated with doctors professional use of social media. To explore ways in which doctors can most appropriately respond to patient feedback and contacts via online platforms.
Participants are equipped to apply the knowledge gained in the webinar to risk assess and safely manage their online activities.
Provides guidance to enable improvement of personal practice in this area:
Royal Pharmaceutical Society UCL School of Pharmacy New Year Lecture 20193GDR
Diabetes and the Pharmacy Army
Philip Newland-Jones
Consultant Pharmacist Diabetes & Endocrinology
University Hospital Southampton NHS Foundation Trust
Mobile Health: the enable of Empowered Patients3GDR
Draft of slides for talk by David Doherty (coFounder, 3GDoctor) at the "Transforming Community Pharmacies in to High Street Clinics" Conference in London on the 15th November 2018.
For more information please visit:
https://mhealthinsight.com/2018/10/28/join-us-at-transforming-community-pharmacies-in-to-high-street-clinics/
Mobile Health: the enable of Empowered Patients3GDR
Draft of slides for talk by David Doherty (coFounder, 3GDoctor) at the "Transforming Community Pharmacies in to High Street Clinics" Conference in London on the 15th November 2018.
Slides for lecture by David Doherty (about.me/mHealth) to the Medical Students at University College Dublin on Thursday 29th March 2018.
Full details and Video:
https://mhealthinsight.com/2018/03/22/how-would-the-bornmobile-generation-redesign-medicine-and-whats-the-future-role-of-the-doctor/
Slides for lecture by David Doherty (about.me/mHealth) to the Medical Students at University College Dublin on Thursday 22 March 2018.
Full details and Video:
https://mhealthinsight.com/2018/03/22/how-would-the-bornmobile-generation-redesign-medicine-and-whats-the-future-role-of-the-doctor/
eHealth Ireland & Northern Ireland Connected Health Ecosystem
members of the ECHAlliance International Ecosystem Network
Cross Border Collaboration Projects in Action Alan Connor, mPower Programme Manager, NHS24
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future”...3GDR
The following slides are notes made by David Doherty following a very interesting presentation on “Pricing and evaluating Orphan Drugs – present and future” provided by Goran Medic, Market Access Manager Europe at Horizon Pharma Plc at the Pharma Pricing & Market Access Europe Conference in London (the world’s largest gathering of pharmaceutical pricing, market access and reimbursement professionals) on the 23rd February 2017.
Deriving more value from real world evidence to ensure timely access of medic...3GDR
Dr Sarah Wamala Andersson, Consultant, Real world evidence and value-based medicines
Pharma Pricing & Market Access Congress 2017 22 February 2017 London
The Future of E-commerce: first-hands insights.Solvd, Inc.
According to Statista, revenue in the e-commerce market is projected to reach US$4,117.00bn in 2024. New technologies and methodologies constantly influence how the e-commerce market develops and shapes itsthe future of e-commerce. The main questions are in the air: How can we stay aligned with e-commerce business owners and ensure our engineering services meet their evolving needs?
At Solvd, this question prompted a deep dive into the current e-commerce landscape. Our goal was to get information about the future of e-commerce directly from first-hand sources. In the course of our research, we explored:
- Portrait of respondents.
- Current challenges and pain points of the e-commerce industry.
- Emerging trends and upcoming opportunities.
- Human resource allocation for e-commerce projects.
- Solutions and actionable advice for business owners.
- The role of a reliable partner in problem-solving.
Explore, download, and share invaluable insights made by Solvd!
It’s no secret that the marketing landscape is growing increasingly complex, with numerous channels, privacy regulations, signal loss, and more. One of the biggest problems facing marketers today is that they’re experiencing data deluge and data drought simultaneously.
Bliss Point by Tinuti addresses these challenges by providing a single, user-friendly platform for measuring what marketers previously struggled to measure. With Bliss Point, you can move beyond simply validating past actions and instead use measurement to guide real-time decision-making on what should happen next.
Join our product experts for a live demonstration of Bliss Point. Discover how it can empower your brand with the tools and insights needed to optimize each channel, across your entire media mix, and your overall brand performance.
1. Structural market access challenges
in anti-infectives
Keiko Tone, VP Market Access
Shionogi Limited
Pharma Pricing and Market Access Congress 2017
Feb, 2017
2. 2Antimicrobial resistance (AMR) is a major
global threat to humanity
If resistance not addressed:
• 10m deaths in 2050
• Largest cause of death,
greater than cancer
GDP impact due to increased
premature deaths estimated to
be $100 Trillion
Source: https://amr-review.org/infographics.html, http://www.bbc.co.uk/guides/z8kccdm (Accessed on 16th Feb 17)
3. 3
• Establish a Global Innovation Fund for early-stage
and non-commercial research
• Better incentives to promote investment for new
drugs and improving existing ones
Global leaders agree that the need for
incentivising investment for new drugs
AMR was one of the top topics for 2016 across major
global forums
3
Firstly, the specific steps to reduce demand
Secondly, we must increase the number of effective
antimicrobial drugs to defeat infections that have become
resistant to existing medicines
Extract from AMR Review Final Report Executive Summary
G7
UN Gen.
Assembly
Source: http://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf
G20
4. 4What makes the anti-infectives business
model challenging
“Save the best to the last”
Very heterogeneous local epidemiology.
Uncertain evolution of future resistance/epi
Data package “Less than comprehensive”
Less than what typically payers would like to
see
1
2
3
5. 5
“Save the best to the last”
Source: https://amr-review.org/sites/default/files/ENPV-1_0.png
• New drugs should be used appropriately
• Volume initially limited even if (or esp when) the new
product is considered to be good
• Many companies left anti-infectives, hence limited new
launches -> Often drugs used today are old and cheap
1
6. 6Epidemiology is uncertain and
heterogeneous
Carbapenem-resistant Acinetobacter spp.
2
• How will resistance pattern be in 3, 5,
10 years?
• What resistance mechanisms will be
the future concern?
Source: ECDC
7. 7
Data package “Less than comprehensive”
Source: https://www.scottishmedicines.org.uk/SMC_Advice/Advice/1146_16_ceftolozane_tazobactam_Zerbaxa
Data package “Less than comprehensive”
• Non-inferiority and descriptive study designs
• For multidrug resistance (MDR), what is the right
comparator? (as other drugs are already resistant). Often
limited data from resistant infection available
• Challenges in defining “Infection caused” mortality and
resource use
3
8. 8
Heterogeneous
and uncertain
epidemiology
Data package
“Less than
comprehensive”
What could pharma companies do?
“Save the best to
the last”
• Understand who are the patients
for your new drug
• Reflect that in your strategy and
economics
• Start early on collecting such
data. Make data as locally
relevant as possible
• Tailor the offers
1
2
3 • Establish SoC and epidemiology
• What other data beyond clinical
studies are meaningful?
• Engage local medical
community early
9. 9Will there be measures to address the
broken model?
• AMR continues to be one of the priority topics at
global forums, e.g., 2017 G20 in Germany
• Decoupling the volume and price is the main theme
discussed in different forums, e.g., AMR Review
report
• What level (e.g., global, country, regions, or hospital
level) would the change likely to happen?
• How long will it take for a global alignment?
• Unlikely that 1 country starts additional funding or
new economic model to stimulate R&D -> the
discussion has to be addressing the local needs
10. 10
Final personal remarks
• Global mobility – issues elsewhere could be your local
issue in the near future
• “Life or death”, no treatment options
• Short term answers and long term answers are both
needed